Egalet’s management team has extensive experience in the pharmaceutical and biotechnology industry and has a track record of successfully developing and commercializing products.
President and Chief Executive Officer
Mr. Radie is president, chief executive officer and a member of Egalet’s board of directors and has been since March 2012. Mr. Radie has had a successful career with more than three decades in the industry and has been responsible for the sale of five companies. In 2005 Mr. Radie led the sale of Vicuron Pharmaceuticals to Pfizer for $1.9 billion and most recently he was responsible for the sale of Topaz Pharmaceuticals Inc. to Sanofi Pasteur for an undisclosed amount. Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Prestwick Pharmaceuticals, Inc., Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and served as a director of Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014, when a majority of Affinium’s assets were acquired by a third party. Mr. Radie began his career in the life sciences at Eli Lilly and Company where he worked for 18 years in sales and marketing positions with increasing levels of responsibility. Mr. Radie serves on the board of Paratek Pharmaceuticals, a biopharmaceutical company, Pennsylvania Bio, an industry group supporting Pennsylvania life sciences companies, Veloxis, a public commercial-stage company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie received his B.S. in chemistry from Boston College.
Chief Financial Officer
Mr. Musial has served as our chief financial officer since April 2013. From June 2011 to March 2013, Mr. Musial was self-employed, acting as an independent consultant in the fields of financial management and accounting services. From January 2005 to May 2011, Mr. Musial served as chief financial officer of Prism Pharmaceuticals, Inc., a specialty pharmaceutical and drug development company. Prior to joining Prism Pharmaceuticals, Mr. Musial was vice president, finance, and chief financial officer for Strategic Diagnostics, Inc., a publicly held biotechnology company, from 2002 to 2004. Mr. Musial began his career with KPMG LLP, a professional services company. Mr. Musial received a B.S. in accounting from the Pennsylvania State University and an M.B.A. from Temple University. He is a certified public accountant in the Commonwealth of Pennsylvania.
Mark Strobeck, Ph.D.
Executive Vice President and Chief Operating Officer
Dr. Strobeck is executive vice president and chief operating officer, a position he’s held since October 2015. He joined Egalet in February 2014 as chief business officer (CBO). Previously Dr. Strobeck was president and chief executive officer of Corridor Pharmaceuticals which he successfully sold to AstraZeneca and chief business officer of Topaz Pharmaceuticals which he sold to Sanofi Pasteur. Dr. Strobeck was chief business officer at Trevena Inc., and vice president of business development at GlaxoSmithKline. Before working at these healthcare companies, Dr. Strobeck was a venture capitalist at SR One Ltd., the wholly owned venture capital arm of GSK and Euclid SR Partners.
Dr. Strobeck earned a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati, completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania and received his bachelor’s degree from St. Lawrence University.
Barbara A. Carlin
Chief Accounting Officer
Ms. Carlin is our chief accounting officer a position she’s held since January 2016. She joined Egalet in January 2014 as vice president, finance and administration. For more than 15 years Ms. Carlin has provided financial and operational leadership to public and privately held companies with a focus on the emerging growth life sciences community. During that time, she worked at several biotechnology and specialty pharmaceutical companies including: Topaz Pharmaceuticals Inc., moksha8 Pharmaceuticals, Inc., Genaera Corporation and Vicuron Pharmaceuticals, Inc. She also served in various roles in finance and accounting at publically held companies in the professional services and publishing space. Ms. Carlin started her career in accounting at Deloitte and Touche LLP. She earned her bachelor’s degree in accounting from St. Joseph’s University and is a certified public accountant in the Commonwealth of Pennsylvania.
E. Blair Clark-Schoeb
Senior Vice President, Communications
Ms. Clark-Schoeb, senior vice president, communications, leads our investor relations, public relations, advocacy relations and government affairs work. She has two decades of experience helping healthcare companies develop unique and effective communications programs. Prior to joining Egalet in February 2015, Ms. Clark-Schoeb led her own consulting business, working with pharmaceutical and biotechnology companies such as Sanofi, Syndax, Horizon Pharmaceuticals and Topaz Pharmaceuticals. Prior to that she was senior associate at W2O, director of investor relations at Burns McClellan, director of corporate finance at The Medicines Company and a healthcare investment banker at Donaldson, Lufkin and Jenrette. Ms. Clark-Schoeb received her bachelor’s degree from Harvard University.
Jeffrey M. Dayno, M.D.
Chief Medical Officer
Dr. Jeffrey Dayno joined Egalet as our chief medical officer in July 2014. He spent ten years in clinical and academic medicine before moving into the pharmaceutical industry. He served as vice president, global medical affairs at ViroPharma, Inc., from August 2011 to May 2014. Prior to joining ViroPharma, Dr. Dayno was the chief medical officer at Labopharm, Inc., a drug delivery technology company based in Montreal, Canada, where he first started working in the field of abuse-deterrent opioid product development. Before Labopharm, he was vice president of medical affairs at Cephalon, Inc., from 2005 to 2010. Dr. Dayno started his career in the pharmaceutical industry in 1998 at Merck & Co., Inc., where he spent 7 years in positions of increasing responsibility in the medical and scientific affairs division. Before moving into leadership roles in the pharmaceutical and biotechnology industry, he held a number of clinical appointments, including assistant professor of neurology, Jefferson Medical College, and medical director of the Jefferson Health System Stroke Center Network. Dr. Dayno earned his medical degree from Temple University School of Medicine, completed a fellowship in stroke and cerebrovascular disorders in the Department of Neurology at Henry Ford Hospital, a National Institutes of Health (NIH) Clinical Research Center for stroke and headache, and was board certified in neurology. Dr. Dayno is currently a member of the Board of Visitors of Temple University School of Medicine and was a former chairman of the Philadelphia Stroke Council.
Karsten Lindhardt, M.Sc., Ph.D.
Senior Vice President, Research and Development
Dr. Lindhardt has been our senior vice president of research and development since December 2013. From April 2011 to December 2013, he served as vice president, research and development, and previously served as our senior director of portfolio management and alliance manager from March 2010 to April 2011. From August 2008 to March 2010, Dr. Lindhardt served as the director of portfolio management for our predecessor Egalet A/S, and as a project manager from March 2008 to August 2008. Before joining Egalet A/S, Dr. Lindhardt served in management positions for Curalogic A/S and OSI Pharmaceuticals, and as a clinical pharmacologist for Ferring Pharmaceuticals and Novo Nordisk A/S. Dr. Lindhardt received an M.Sci. in Pharmaceutics, a Ph.D. in pharmaceutical development and pharmacology, each from the Royal Danish School of Pharmacy, and a Diploma of Business Excellence (DBE) from Columbia University and Copenhagen Business School.
Chief Commercial Officer
Mr. Shea serves as Egalet’s chief commercial officer and has held this position since he joined the company in September 2016. Mr. Shea has over two decades of sales, marketing, market access and commercial operations experience. He most recently served as CCO at Clarus Therapeutics, Inc., a men’s health specialty pharmaceutical company. Prior to Clarus he served as vice president of sales and marketing for the U.S. commercial operations of CSL Behring, where he oversaw strategic efforts for sales, marketing and managed care business. Before that he was as senior vice president of sales and marketing for the U.S. pharmaceutical operations at Astellas Pharmaceuticals, and held senior sales and marketing roles at Ligand Pharmaceuticals and Boehringer Ingelheim. Mr. Shea received his bachelor’s degree in Psychology from Alfred University.